Twenty years ago, Roger Cone, Ph.D. made a key discovery in obesity science which could help Courage Therapeutics deliver ...

Life sciences companies can look to the automotive industry for ideas about collaborating with patients to co-create new ...

By sharing early-stage tools and data openly, life sciences companies can minimize duplication and de-risk R&D without ...

A key focus of Part III in this clinical trial payment series is the tax implications of trial payments. This article emphasizes that while reimbursements for out-of-pocket expenses are tax-exempt and ...

On this weeks Business of Biotech, Dr. Hernan Bazan, M.D., co-founder and CEO at New Orleans-based South Rampart Pharma, talks about building an ultra-lean drug development company to address an unmet ...

Chris Anzalone, CEO of Arrowhead Pharmaceuticals, discusses overcoming adversity while leading the company through challenging times.

As the use of AI increases and expands to new functional areas within biopharmaceutical companies, leaders must understand the risks and mitigate the impact of hallucinations in AI model outputs.

Cybin CEO Doug Drysdale discusses learnings from psychedelic drug clinical trial missteps, provides examples of the benefits of FDA breakthrough therapy designation, and talks about why RFK Jr. as HHS ...

Big Pharma incubators offer unique funding and innovation opportunities for emerging biopharma companies, and strong sources of external innovation for incubator host organizations.

Mental health has become one of the significant factors determining early retirement, disability benefits, absenteeism levels, and high societal costs such as productivity losses and medical treatment ...

Managing risks associated with AI hallucinations requires "explainability," a process that identifies patterns or behaviors in AI models that are inconsistent with training data or logical ...

In the world of biopharmaceutical innovation, groundbreaking scientific discoveries often do not directly translate into commercial success. Simply developing a promising therapeutic based on great ...